Omni Bio Announces Progress of BioMimetix Pharmaceutical for Cancer and Radiation Therapy
News Jan 17, 2012
BioMimetix is a recently formed biopharmaceutical company and intends to develop a new class of compounds of higher potency from previous metalloporphyrin antioxidant mimetics for the treatment of various diseases including radiation toxicity, a frequent side effect of cancer treatment using radiation therapy. BioMimetix is the exclusive licensee of a 2010 issued patent owned by Duke University directed to this new class of compounds. BioMimetix believes that its current development compound, BMX-001, has significantly higher potency than earlier generation compounds. BioMimetix's initial targeted indication for BMX-001 is in glioblastoma, an aggressive brain tumor. Other targeted indications may include radiation therapy in the treatment of head and neck cancer and the treatment of morphine tolerance.
Dr. James Crapo, chief executive officer of Omni Bio and BioMimetix, commented, "We are pleased to communicate that BioMimetix is progressing on plan in its first year of development of a new class of mangano porphyrin (MP) antioxidant mimetics. BioMimetix was successfully launched in July 2011 with its first year capital needs adequately funded. It is proceeding through the GMP synthesis phase of its new molecule, BMX-001, and its goal is to complete preclinical development to enable an IND to be filed and the initiation of human studies in 2012."
An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.READ MORE
The days - or even weeks - spent waiting for the results of a cancer-screening test can feel like an eternity. Especially when early diagnosis and quick action are tied to better outcomes. Now, a new technique to analyze proteins expressed on cancer cells shows promise in more rapidly detecting these cell types.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019